Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating hemangioma and vascular malformation sclerosis and preparation method and application thereof

A composition and technology of hemangioma, applied in the field of medicine, to achieve the effect of improving embolization efficiency, enhancing therapeutic effect, and strong therapeutic effect

Pending Publication Date: 2020-04-03
SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when using bleomycin for hemangiomas and vascular malformations, the lifetime dose (<400 mg or 5 mg / kg) is a limitation to reduce the risk of pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating hemangioma and vascular malformation sclerosis and preparation method and application thereof
  • Pharmaceutical composition for treating hemangioma and vascular malformation sclerosis and preparation method and application thereof
  • Pharmaceutical composition for treating hemangioma and vascular malformation sclerosis and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Embodiment 1 A kind of pharmaceutical composition for the treatment of hemangioma and vascular malformation sclerosis

[0038] Prepare the mixture as follows:

[0039] Bleomycin 0.01mg / ml

[0040] 1% polidocanol injection to make up the remaining volume

[0041] The above-mentioned bleomycin and 1% polidocanol injection are mixed to obtain the pharmaceutical composition. Inject into syringe 1, use a three-way valve to connect syringe 1 with syringe 2 filled with air, quickly push injection 1 and syringe 2, and pump repeatedly for a total of 20 times to make foam.

Embodiment 2

[0042] Embodiment 2 A kind of pharmaceutical composition for the treatment of hemangioma and vascular malformation sclerosis

[0043] Prepare the mixture as follows:

[0044] Bleomycin 50mg / ml

[0045] 0.5% Lauromacrogol Injection Supplement the remaining volume

[0046] The above-mentioned bleomycin and 0.5% polidocanol injection are mixed to obtain the pharmaceutical composition. Inject into syringe 1, use a three-way valve to connect syringe 1 with syringe 2 filled with air, quickly push injection 1 and syringe 2, and pump repeatedly for a total of 20 times to make foam.

Embodiment 3

[0047] Example 3 A pharmaceutical composition for the treatment of hemangioma and vascular malformation sclerosis

[0048] Prepare the mixture as follows:

[0049] Bleomycin 0.2mg / ml

[0050] 3% polidocanol injection to make up the remaining volume

[0051]The above-mentioned bleomycin and 3% polidocanol injection are mixed to obtain the pharmaceutical composition. Inject into syringe 1, use a three-way valve to connect syringe 1 with syringe 2 filled with air, quickly push injection 1 and syringe 2, and pump repeatedly for a total of 20 times to make foam.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating hemangioma or vascular malformation sclerosis. The pharmaceutical composition at least comprises bleomycin and a foam hardener. The invention further discloses a preparation method and application of the pharmaceutical composition. By using the pharmaceutical composition disclosed by the invention, the retention time of bleomycin ina local focus can be prolonged, and the contact area between bleomycin and a lesion vessel is increased. The embolization efficiency is improved, and a better treatment effect is achieved. Accordingto the composition disclosed by the invention, reduction of single dosage of bleomycin is realized, so that bleomycin plays a stronger treatment role within the limit of the lifetime dosage thereof.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a pharmaceutical composition for treating hemangioma and vascular malformation sclerosis, a preparation method and application thereof. Background technique [0002] Hemangiomas and vascular malformations are common diseases caused by abnormal proliferation of endothelial cells or congenital malformation of blood vessels or lymphatic vessels. They often appear at birth, usually on the head and face, and can also involve the limbs and trunk. Hemangiomas and vascular malformations affect the appearance and bring a huge burden to the lives of patients. In severe cases, they may even cause organ displacement, bone deformity, and dysfunction. [0003] At present, there are many drugs used in the sclerosing treatment of hemangioma and vascular malformation. The main sclerosing agents include absolute ethanol, bleomycin (Pingyangmycin), foam sclerosing agents (polidocanol, lauromacrogol, tetra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/14A61K9/12A61K45/06A61K47/20A61K47/10A61P9/14A61P35/00
CPCA61K45/06A61K9/12A61K9/0019A61K38/14A61K47/20A61K47/10A61P9/14A61P35/00A61K2300/00
Inventor 林晓曦陈辉杨希孙怡
Owner SHANGHAI NINTH PEOPLES HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com